Dapagliflozin, peptide YY, and weight loss in heart failure with preserved ejection fraction

Journal Article Dapagliflozin, peptide YY, and weight loss in heart failure with preserved ejection fraction Get access Yogesh N V Reddy, Yogesh N V Reddy The Department of Cardiovascular Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA https://orcid.org/0000-0002-1116-8541 Search for other works by this author on: Oxford Academic PubMed Google Scholar Vojtech Melenovsky, Vojtech Melenovsky Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic https://orcid.org/0000-0001-8921-7078 Search for other works by this author on: Oxford Academic PubMed Google Scholar Aneesh K Asokan, Aneesh K Asokan Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Mayo Clinic, Rochester, MN, USA Search for other works by this author on: Oxford Academic PubMed Google Scholar Martin Haluzik, Martin Haluzik Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic Search for other works by this author on: Oxford Academic PubMed Google Scholar Rickey E Carter, Rickey E Carter Department of Quantitative Health Sciences, Division of Clinical Trials & Biostatistics, Mayo Clinic, Jacksonville, FL, USA Search for other works by this author on: Oxford Academic PubMed Google Scholar Sreekumaran Nair, Sreekumaran Nair Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Mayo Clinic, Rochester, MN, USA Search for other works by this author on: Oxford Academic PubMed Google Scholar Michael D Jensen, Michael D Jensen Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Mayo Clinic, Rochester, MN, USA Search for other works by this author on: Oxford Academic PubMed Google Scholar Barry A Borlaug Barry A Borlaug The Department of Cardiovascular Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA Corresponding author. Tel: +1 507 255 1051, Fax: +1507 266 0228, Email: [email protected] https://orcid.org/0000-0001-9375-0596 Search for other works by this author on: Oxford Academic PubMed Google Scholar European Heart Journal, ehae534, https://doi.org/10.1093/eurheartj/ehae534 Published: 21 August 2024 Article history Received: 28 May 2024 Revision received: 05 July 2024 Accepted: 04 August 2024 Published: 21 August 2024

Authors

Institutions

Publication Details

Journal
European Heart Journal
Published
2024-08-21
DOI
https://doi.org/10.1093/eurheartj/ehae534
Citations
16
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
5.72

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Dapagliflozin, peptide YY, and weight loss in heart failure with preserved ejection fraction

K. Sreekumaran Nair, Michael D. Jensen, Martin Haluzı́k, Rickey E. Carter et al.
16 citations
European Heart Journal
Diabetes Treatment and Management
5.72
article

Dapagliflozin, peptide YY, and weight loss in heart failure with preserved ejection fraction

K. Sreekumaran Nair, Michael D. Jensen, Martin Haluzı́k, Rickey E. Carter, Barry A. Borlaug, Aneesh K Asokan, Vojtěch Melenovský, Yogesh N V Reddy
article en
16 citations

Abstract

Journal Article Dapagliflozin, peptide YY, and weight loss in heart failure with preserved ejection fraction Get access Yogesh N V Reddy, Yogesh N V Reddy The Department of Cardiovascular Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA https://orcid.org/0000-0002-1116-8541 Search for other works by this author on: Oxford Academic PubMed Google Scholar Vojtech Melenovsky, Vojtech Melenovsky Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic https://orcid.org/0000-0001-8921-7078 Search for other works by this author on: Oxford Academic PubMed Google Scholar Aneesh K Asokan, Aneesh K Asokan Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Mayo Clinic, Rochester, MN, USA Search for other works by this author on: Oxford Academic PubMed Google Scholar Martin Haluzik, Martin Haluzik Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic Search for other works by this author on: Oxford Academic PubMed Google Scholar Rickey E Carter, Rickey E Carter Department of Quantitative Health Sciences, Division of Clinical Trials & Biostatistics, Mayo Clinic, Jacksonville, FL, USA Search for other works by this author on: Oxford Academic PubMed Google Scholar Sreekumaran Nair, Sreekumaran Nair Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Mayo Clinic, Rochester, MN, USA Search for other works by this author on: Oxford Academic PubMed Google Scholar Michael D Jensen, Michael D Jensen Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Mayo Clinic, Rochester, MN, USA Search for other works by this author on: Oxford Academic PubMed Google Scholar Barry A Borlaug Barry A Borlaug The Department of Cardiovascular Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA Corresponding author. Tel: +1 507 255 1051, Fax: +1507 266 0228, Email: [email protected] https://orcid.org/0000-0001-9375-0596 Search for other works by this author on: Oxford Academic PubMed Google Scholar European Heart Journal, ehae534, https://doi.org/10.1093/eurheartj/ehae534 Published: 21 August 2024 Article history Received: 28 May 2024 Revision received: 05 July 2024 Accepted: 04 August 2024 Published: 21 August 2024

European Heart JournalVol. 45(37)
Mayo Clinic (US), Mayo Clinic in Arizona (US), Institute of Clinical and Experimental Medicine (CZ), Mayo Clinic in Florida (US)
U.S. Department of Defense, Mayo Clinic, Amgen, Eli Lilly and Company, AstraZeneca, Bayer, GlaxoSmithKline, Sanofi, Edwards Lifesciences, Cytokinetics, Tenax Therapeutics, European Commission, Ministerstvo Zdravotnictví Ceské Republiky, Novo Nordisk, United Pharmaceuticals, Norges Idrettshøgskole, National Institutes of Health, National Heart, Lung, and Blood Institute
Good health and well-being
Openalex Percentile: Top 3%
Diabetes Treatment and Management
5.72
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.